Colorectal carcinoma

This phase 2 trial tests whether adding an experimental drug called pixatimod to the immunotherapy nivolumab can shrink tumors in people with advanced melanoma, non-small cell lung cancer, or colorectal cancer that has stopped responding to prior treatment. One group with colorec…

This early-stage trial is testing whether a pill made from freeze-dried healthy donor stool (MTP-101P) is safe and can restore good bacteria in people having part of their colon removed. Forty adults aged 18-75 with colon polyps, early-stage cancer, or diverticulitis will take th…

This study tested a special pump placed under the skin that sends chemotherapy directly to the liver through the hepatic artery. It was for people with colorectal cancer that had spread to the liver and who had already tried other chemotherapies. The goal was to see if this direc…

This early-phase study tested an experimental drug called COM902, alone or with other drugs, in 94 people with advanced cancers like ovarian, lung, and colon cancer. The main goal was to check safety and find the right dose. Researchers also looked for early signs that the drug m…

This trial tests an experimental virus-based therapy called JX-594 (Pexa-Vec) in people with advanced colorectal cancer that has not responded to standard treatments. The virus is designed to infect and kill cancer cells while also stimulating the immune system. It is given alone…

This study tests a new drug called pegilodecakin, a lab-made version of a natural immune protein (interleukin-10), in people with advanced solid tumors such as melanoma, lung, breast, prostate, ovarian, kidney, colorectal, and pancreatic cancers. The drug is given as a daily shot…

This early-phase trial tests a modified virus called JX-594 (Pexa-Vec) in people with advanced colorectal cancer that has not responded to standard treatments. The virus is designed to infect and kill cancer cells while also stimulating the immune system. The main goal is to chec…

This early-phase trial tested two drugs together—pembrolizumab (Keytruda) and XL888—in 47 people with advanced gastrointestinal cancers like colorectal and pancreatic cancer that had spread or could not be removed. The main goal was to find the safest dose and check for side effe…

This registry followed 152 patients with colorectal cancer that had spread mainly to the liver. Doctors used tiny beads called LifePearl Microspheres loaded with the chemotherapy drug irinotecan, delivered directly to the liver's blood supply. The goal was to see how and when thi…

This early-phase study tested a combination of two drugs, cabozantinib and TAS-102, in 15 people with advanced colorectal cancer that had spread and stopped responding to standard treatments. The main goal was to find the safest dose and identify side effects. The study is comple…

This early-phase trial tested an experimental drug called BAT8010 in 23 people with advanced or metastatic solid tumors who had no other standard treatment options. The main goals were to check safety, find the best dose, and see if the drug shows any sign of shrinking tumors. Pa…

This early-phase study tested a personalized immunotherapy (iNeo-Vac-P01) in 6 patients with stage III colorectal or non-small cell lung cancer who had already completed surgery and standard adjuvant therapy. The vaccine was designed to target unique neoantigens from each patient…

This study tested a combination of two drugs—NT-I7 (efineptakin alfa) and pembrolizumab (Keytruda)—in 215 people with advanced solid tumors that had stopped responding to treatment. The goal was to check safety, find the right dose, and see if the combo could shrink tumors. The t…

This completed Phase 2 trial tested whether combining an immunotherapy drug (durvalumab) with an epigenetic drug (tazemetostat) can control advanced solid tumors like pancreatic, colorectal, and soft-tissue sarcoma. The study enrolled 164 adults and measured how well the combo sh…

This phase 2 trial tested a three-part treatment for people with colorectal cancer that spread to the liver and stopped responding to standard treatments. The approach combines two minimally invasive procedures (TACE and HAIC) with the targeted drug regorafenib. The goal was to s…

This phase II trial tested a combination of three drugs—TAS-102, irinotecan, and bevacizumab—in 42 people with advanced colorectal cancer that had spread or couldn't be removed. The goal was to see if this mix could slow tumor growth better than standard treatments. Participants …

This phase II trial tested two different drug combinations in 240 people with advanced HER2-positive colorectal cancer that had spread and could not be removed by surgery. One group received the antibodies trastuzumab and pertuzumab, while the other received cetuximab (an antibod…

This early-phase study tested a new drug called SHR-A1811 in 101 people with advanced stomach or colorectal cancers that have a specific protein called HER2. The main goals were to check the drug's safety, find the best dose, and see early signs of tumor shrinkage. Participants h…

This early-phase study tests two experimental drugs, BI 765049 and ezabenlimab, in adults with advanced solid tumors like colorectal, lung, and pancreatic cancer. The main goal is to find the highest safe dose of BI 765049 alone and in combination with ezabenlimab. Participants r…

This phase 1 trial tested a combination of regorafenib (a targeted therapy) plus two immunotherapy drugs (nivolumab and ipilimumab) in 39 patients with advanced colorectal cancer that had spread and stopped responding to chemotherapy. The goal was to find the safest dose and chec…

This early-phase trial tested a new oral drug called JAB-21822, alone or with cetuximab, in 29 adults with advanced solid tumors (like lung or colorectal cancer) that have a specific KRAS G12C mutation. The main goals were to check safety and find the right dose. Participants had…

This early-phase trial tested a combination of three drugs—utomilumab, cetuximab, and irinotecan—in 34 patients with advanced colorectal cancer that had spread and stopped responding to standard treatment. The goal was to find the safest dose and check for side effects. While the…

This study tested a combination of nivolumab (Opdivo) and trametinib (Mekinist), with or without ipilimumab (Yervoy), in 325 people whose colorectal cancer had spread and had not responded to prior treatments. The main goals were to check safety and see if the drugs could shrink …

This early-stage trial tested a new drug called CFT1946, alone or with other drugs, in 89 adults with solid tumors that have a BRAF V600 mutation, including melanoma, lung, colon, and thyroid cancers. The main goals were to check safety and find the best dose. The study is comple…

This study tested whether the immunotherapy drug nivolumab, alone or with other drugs, can shrink tumors in people with colon cancer that has returned or spread. It included 385 participants whose tumors had a specific genetic feature called MSI-H or were non-MSI-H. The goal was …

This study tested a combination of three drugs (encorafenib, binimetinib, and cetuximab) given before surgery to people with a specific type of colorectal cancer that has a BRAF V600E mutation. Only 2 patients took part. The goal was to see how much the tumor shrank and to check …

This study tests whether a new imaging tracer called 18F-PSMA-1007 can better detect liver metastases in people with colorectal cancer. Participants receive an injection of the tracer and then undergo a PET/CT scan. The goal is to see if this method finds the same liver lesions a…

This study looked at whether mindfulness exercises can lower stress and improve communication between patients with liver disease and their doctors. 56 adults took part, answering surveys about their stress, anxiety, and how well they felt they could share decisions with their he…

This study tested whether sending personalized text messages could help colorectal cancer survivors eat more whole grains and less refined grains. Forty-six survivors who had finished active treatment received text messages and nutrition materials. The main goal was to see if peo…

This study tested whether an online program combining nutrition counseling and resistance training could improve physical function in older adults (65+) who finished treatment for breast, colorectal, or prostate cancer. 75 participants received virtual sessions with dietitians an…

This large Italian study investigates whether a composite measure called 'Textbook Outcome' can serve as a reliable indicator of quality in colorectal cancer surgery. Researchers will analyze data from over 6,000 patients to see if meeting six key criteria—including survival, com…

This completed study took small tissue samples from the colons of 40 people during routine colonoscopies. Using advanced genetic techniques, researchers created a detailed map of the different cell types and their gene activity. The goal is to better understand how colon diseases…

This study tested whether a theory-based chatbot could increase colorectal cancer screening rates. 500 adults aged 50-75 in Hong Kong were randomly assigned to receive either standard text reminders or a chatbot that provided personalized risk information and screening guidance. …

This study looked for leftover cancer DNA in the blood of over 2,000 people who had surgery for stage II or III colorectal cancer. Participants did not receive any new treatment—they just gave blood samples over about 21 months. The goal was to find patients who might be eligible…

This study looked at 150 colorectal cancer patients to see if counting tumor buds in biopsy samples could predict whether cancer has spread to lymph nodes or other organs. Researchers used a special stain to find tumor buds and counted them in the densest area. They then used a c…

This study looked at whether cancer survivors living in rural areas can create their own survivorship care plans and learn from telehealth education. 261 survivors of breast, colorectal, lung, lymphoma, or prostate cancer took part. The goal was to see if this approach improves t…

This study looked at tiny particles called microparticles in the blood of 41 people with colorectal cancer that had spread to the lining of the abdomen. The goal was to see if these particles could serve as a better way to detect this spread early, compared to current tests. Rese…

This pilot study tested whether advanced genetic sequencing of tumors can be done quickly enough to guide treatment decisions. Researchers took blood and tumor samples from 24 adults with advanced soft-tissue sarcoma or metastatic colorectal cancer. They measured how long it took…